amifostine anhydrous has been researched along with Cancer of Head in 112 studies
Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Professionals discussed a novel treatment (Irinotecan) for advanced colorectal cancers; a unique anticancer agent (Docetaxel) effective in hard-to-treat head and neck cancer; a highly active neoadjuvant chemotherapy regimen for operable breast cancer; and a cytoprotective agent (Amifostine) capable of protecting normal tissue from radiation and chemotherapeutic toxicity." | 3.69 | Highlights of the Eighth European Cancer Conference. ( Prescott, LM, 1995) |
| "Patients with newly diagnosed squamous cell carcinoma of the head and neck, who were eligible for radiotherapy and who were not receiving concurrent chemotherapy, were randomly assigned to receive either IV amifostine (200 mg/m(2) daily for 3 minutes, 15 to 30 minutes before irradiation) or SC amifostine (500 mg; two sites; 20 to 60 minutes before irradiation)." | 2.76 | Subcutaneous compared with intravenous administration of amifostine in patients with head and neck cancer receiving radiotherapy: final results of the GORTEC2000-02 phase III randomized trial. ( Alfonsi, M; Aupérin, A; Bardet, E; Boisselier, P; Bourhis, J; Calais, G; Dessard-Diana, B; Feham, NE; Garaud, P; Martin, L; Seng, SH; Tuchais, C, 2011) |
| " There were no reports of Grade >/=3 amifostine-related adverse events." | 2.73 | Efficacy and safety of subcutaneous amifostine in minimizing radiation-induced toxicities in patients receiving combined-modality treatment for squamous cell carcinoma of the head and neck. ( Christie, D; Kennedy, T; Law, A; Pellitteri, P; Wood, C; Yumen, O, 2007) |
| "Sixty-seven head and neck cancer patients were randomized to receive radiotherapy or radiotherapy plus Amifostine." | 2.72 | Effect of Amifostine to prevent radiotherapy-induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland function. ( Aekmahachai, M; Chiewvit, S; Chitapanarux, I; Khorprasert, C; Kongthanarat, Y; Lorvidhaya, V; Panichevaluk, A; Phromratanapongse, P; Pusuwan, P; Ratchadara, S; Saengsuda, Y; Shotelersuk, K; Sirilipoche, S; Sukthomya, V; Suntornpong, N; Swangsilpa, T; Tesavibul, C; Veerasarn, V, 2006) |
| "Oral candidiasis is suggested as an objective, early, though indirect, endpoint for amifostine's radioprotective effect on salivary glands." | 2.71 | Oral candidiasis in head and neck cancer patients receiving radiotherapy with amifostine cytoprotection. ( Dardoufas, K; Kolitsi, G; Kouloulias, V; Kyprianou, K; Nicolatou-Galitis, O; Papanikolaou, I; Pissakas, G; Sotiropoulou-Lontou, A; Velegraki, A; Yiotakis, I, 2003) |
| "As for acute xerostomia, patients with laryngeal cancer were excluded from evaluation." | 2.71 | Randomized phase III trial of postoperative radiochemotherapy +/- amifostine in head and neck cancer. Is there evidence for radioprotection? ( Fehlauer, F; Feyerabend, T; Hinke, A; Mahlmann, B; Marx, M; Richter, E; Sommer, K; Vacha, P, 2003) |
| "The treatment of head and neck cancer continues to evolve." | 2.71 | Phase II randomized study of concomitant chemoradiation using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with newly diagnosed locally advanced squamous cell carcinoma of the head and neck. ( Costello, R; Haddad, R; Posner, M; Weeks, L; Wirth, L, 2003) |
| "Xerostomia is the most prevalent late side effect of radiation for head and neck malignancies and is cited by patients as the major cause of decreased quality of life." | 2.71 | Pilot study of subcutaneous amifostine in patients undergoing postoperative intensity modulated radiation therapy for head and neck cancer: preliminary data. ( Chao, KS; Haughey, B; Thorstad, WL, 2003) |
| " This is the first report focusing on amifostine related adverse effects leading to discontinuation of amifostine treatment." | 2.71 | Serious adverse effects of amifostine during radiotherapy in head and neck cancer patients. ( Alberti, W; Bajrovic, A; Fehlauer, F; Mahlmann, B; Rades, D; Richter, E, 2004) |
| "Xerostomia is one of the most prevalent late side effects of radiation for head and neck malignancies, and patients cite it as the major cause of decreased quality of life." | 2.71 | Toxicity and compliance of subcutaneous amifostine in patients undergoing postoperative intensity-modulated radiation therapy for head and neck cancer. ( Chao, KS; Haughey, B; Thorstad, WL, 2004) |
| "Adults with head-and-neck cancer who underwent once-daily RT for 5-7 weeks (total dose, 50-70 Gy) received either open-label amifostine (200 mg/m2 i." | 2.71 | Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head-and- neck cancer: 2-year follow-up of a prospective, randomized, phase III trial. ( Brizel, DM; Eschwege, F; Henke, M; Monnier, A; Sauer, R; Strnad, V; Wasserman, TH, 2005) |
| "Xerostomia was scored subjectively and by whole saliva measurements." | 2.70 | Tools for optimal tissue sparing in concomitant chemoradiation of advanced head and neck cancer: subcutaneous amifostine and computed tomography-based target delineation. ( Braaksma, M; Levendag, P, 2002) |
| "A phase II trial of SC amifostine in head and neck cancer was performed in a patient population (n = 54) similar to that studied in a phase III trial of intravenous amifostine to allow comparisons of outcomes." | 2.70 | Phase II trial of subcutaneous amifostine in patients undergoing radiation therapy for head and neck cancer. ( Anné, PR, 2002) |
| "28 patients with squamous cell carcinomas of the head and neck received adjunctive or primary radiotherapy (5 days per week with daily fractions of 2 Gy, up to a total dose of 60 Gy) in conjunction with carboplatin (70 mg/m2) on days 1-5 and days 21-26." | 2.70 | Economic analysis of amifostine as adjunctive support for patients with advanced head and neck cancer: preliminary results from a randomized phase II clinical trial from Germany. ( Bennett, CL; Buntzel, J; Glatzel, M; Lane, D; Stinson, T, 2001) |
| "Patients with head and neck cancer received radiotherapy (2 Gy/day 5 days a week up to 60 Gy) with carboplatin 70 mg/m2 on days 1-5 and 21-25 inclusive." | 2.69 | Radiochemotherapy with amifostine cytoprotection for head and neck cancer. ( Büntzel, J; Glatzel, M; Küttner, K; Schuth, J, 1998) |
| "Twenty-three patients with advanced head and neck cancer, mainly Stage III and IV, were treated with preoperative radiation (n = 1), pre- as well as postoperative radiotherapy (n = 5), postoperative radiation (n = 9) or combined postoperative radio-chemotherapy (n = 6)." | 2.69 | [Cytoprotection with amifostine in radiotherapy or radio-chemotherapy of head and neck tumors]. ( Altmann, S; Hoffmanns, H, 1999) |
| "Radiotherapy for head and neck cancer causes acute and chronic xerostomia and acute mucositis." | 2.69 | Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. ( Brizel, DM; Eschwege, F; Henke, M; Monnier, A; Oster, W; Rudat, V; Russell, L; Sauer, R; Strnad, V; Wasserman, TH; Zhang, J, 2000) |
| "Although head and neck cancer is not one of the most common cancers, it is a debilitating disease with poor prognosis and considerable post-treatment normal tissue toxicity." | 2.45 | The role of amifostine in the treatment of head and neck cancer with cisplatin-radiotherapy. ( Marcu, LG, 2009) |
| "From a prognosis perspective, head and neck cancers are a heterogeneous group of diseases." | 2.44 | Clinical trial design limitations in head and neck squamous cell carcinomas. ( Awada, A; Bogaerts, J; Lacombe, D; Yun, HJ, 2007) |
| "Xerostomia is a permanent and devastating sequela of head and neck irradiation, and its consequences are numerous." | 2.43 | Management of xerostomia related to radiotherapy for head and neck cancer. ( Johnstone, PA; Kahn, ST, 2005) |
| "Radiation for head and neck cancers is often curative, but high doses are used." | 2.43 | How to reduce radiation-related toxicity in patients with cancer of the head and neck. ( Chambers, MS; Garden, AS; Lewin, JS, 2006) |
| "Pilocarpine is a useful agent as a treatment of radiation-induced xerostomia in head and neck cancer patients." | 2.43 | Evaluation, prevention and management of radiotherapy-induced xerostomia in head and neck cancer patients. ( de Castro, G; Federico, MH, 2006) |
| "Mucositis is a significant complication of cancer therapy, with important clinical and economic implications." | 2.43 | Amifostine in the management of radiation-induced and chemo-induced mucositis. ( Bensadoun, RJ; Keefe, D; Lalla, RV; Schubert, MM, 2006) |
| "Mucositis was scored by either the WHO, the National Cancer Institute-Common Toxicity Criteria (NCI-CTC) score, or the absence or presence of ulcerations, or the presence or absence of grades 3 and 4 mucositis." | 2.43 | Preventive intervention possibilities in radiotherapy- and chemotherapy-induced oral mucositis: results of meta-analyses. ( Boezen, HM; de Vries, EG; Roodenburg, JL; Schouten, JP; Spijkervet, FK; Stokman, MA, 2006) |
| "Dry mouth (xerostomia) is one of the most common complaints following radiation therapy (RT) for head and neck cancers." | 2.42 | Radiotherapy-induced salivary dysfunction. ( Hu, K; Ship, JA, 2004) |
| "Patients diagnosed with head and neck cancer face a myriad of treatment options." | 2.41 | Head and neck cancer: managing xerostomia and other treatment induced side effects. ( Gosselin, TK; Pavilonis, H, 2002) |
| "Radiodermatitis and radioinduced oral mucositis are frequent and significant side effects among patients with breast and head and neck cancer, respectively." | 1.51 | Preventing Radiation-Induced Injury by Topical Application of an Amifostine Metabolite-Loaded Thermogel. ( Benel, L; Bloy, C; Bricout, D; Chargari, C; Clémenson, C; Deutsch, E; Haddad, R; Liu, W; Mondini, M; Soyez-Herkert, L; Wang-Zhang, X, 2019) |
| "Orally administered AMF achieves a similar systemic bioavailability and decreased peak plasma level of WR-1065 compared to intravenously administered AMF, suggesting oral AMF formulations maintain radioprotective efficacy without causing onerous side effects, and are clinically feasible." | 1.48 | Novel Formulation Strategy to Improve the Feasibility of Amifostine Administration. ( Buchman, L; Buchman, SR; Donneys, A; Lipka, E; Lynn, J; Nelson, N; Ranganathan, K; Reyna, D; Rodriguez, J; Simon, E; Snider, A; Zhang, Y, 2018) |
| "Head and neck cancer is treated mainly with surgery and radiotherapy." | 1.36 | Amifostine modulates radio-induced apoptosis of peripheral blood lymphocytes in head and neck cancer patients. ( Henríquez-Hernández, LA; Lara, PC; Lloret, M; Pinar, B; Rodríguez-Gallego, C; Saavedra, MM, 2010) |
| "For all the chromosome aberrations considered, a negative correlation between their initial yield and the percentage of this yield remained 12 months after radiotherapy was observed (p < 0." | 1.35 | Cytogenetic damage induced by radiotherapy. Evaluation of protection by amifostine and analysis of chromosome aberrations persistence. ( Barquinero, JF; Barrios, L; Caballín, MR; Craven-Bartle, J; de Vega, JM; Ribas, M; Xunclà, M, 2008) |
| " In addition, dose-response curves were calculated." | 1.34 | Changes in salivary gland function after radiotherapy of head and neck tumors measured by quantitative pertechnetate scintigraphy: comparison of intensity-modulated radiotherapy and conventional radiation therapy with and without Amifostine. ( Debus, J; Haberkorn, U; Herfarth, KK; Hof, H; Hoffner, S; Huber, P; Karger, CP; Münter, MW; Rudat, V, 2007) |
| "Five pediatric patients with head and neck cancers were treated with radiotherapy." | 1.34 | Daily subcutaneous amifostine administration during irradiation of pediatric head and neck cancers. ( Anacak, Y; Haydaroglu, A; Kamer, S, 2007) |
| "By contrast, 60% of the tumors analyzed showed a loss of IAP expression in both epithelial cells and stroma, and only 10% to 15% of them demonstrated nuclear/cytoplasmic reactivity, which was confined to the epithelial cells." | 1.31 | Down-regulation of intestinal-type alkaline phosphatase in the tumor vasculature and stroma provides a strong basis for explaining amifostine selectivity. ( Giatromanolaki, A; Koukourakis, MI; Maltezos, E; Sivridis, E, 2002) |
| "The degree of xerostomia has been reported to depend on the radiation dose and the salivary gland volume irradiated." | 1.31 | Protection of salivary function by intensity-modulated radiation therapy in patients with head and neck cancer. ( Chao, KS, 2002) |
| "Xerostomia has been seen in 15 patients (Grade I) and 5 patients (Grade II) after administration of amifostine." | 1.30 | Amifostine--a radioprotector in locally advanced head and neck tumors. ( Prott, FJ; Schönekäs, KG; Wagner, W, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (3.57) | 18.7374 |
| 1990's | 17 (15.18) | 18.2507 |
| 2000's | 79 (70.54) | 29.6817 |
| 2010's | 12 (10.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ranganathan, K | 1 |
| Simon, E | 1 |
| Lynn, J | 1 |
| Snider, A | 1 |
| Zhang, Y | 1 |
| Nelson, N | 1 |
| Donneys, A | 1 |
| Rodriguez, J | 1 |
| Buchman, L | 1 |
| Reyna, D | 1 |
| Lipka, E | 1 |
| Buchman, SR | 1 |
| Lee, MG | 1 |
| Freeman, AR | 1 |
| Roos, DE | 1 |
| Milner, AD | 1 |
| Borg, MF | 1 |
| Clémenson, C | 1 |
| Liu, W | 1 |
| Bricout, D | 1 |
| Soyez-Herkert, L | 1 |
| Chargari, C | 1 |
| Mondini, M | 1 |
| Haddad, R | 3 |
| Wang-Zhang, X | 1 |
| Benel, L | 1 |
| Bloy, C | 1 |
| Deutsch, E | 2 |
| Gu, J | 1 |
| Zhu, S | 1 |
| Li, X | 1 |
| Wu, H | 1 |
| Li, Y | 2 |
| Hua, F | 1 |
| Blanchard, P | 2 |
| Bourhis, J | 6 |
| Lacas, B | 1 |
| Le Teuff, G | 1 |
| Michiels, S | 1 |
| Pignon, JP | 2 |
| Rudat, V | 5 |
| Münter, M | 1 |
| Rades, D | 2 |
| Grötz, KA | 1 |
| Bajrovic, A | 2 |
| Haberkorn, U | 2 |
| Brenner, W | 1 |
| Debus, J | 2 |
| Mell, LK | 1 |
| Movsas, B | 2 |
| Rosenthal, DI | 6 |
| Trotti, A | 1 |
| Koukourakis, GV | 1 |
| Baksevanis, CN | 1 |
| Zambatis, H | 1 |
| Gritzapis, A | 1 |
| Maltezos, E | 2 |
| Simopoulos, C | 1 |
| Koukourakis, MI | 5 |
| Marcu, LG | 1 |
| Sonis, S | 1 |
| Posner, M | 2 |
| Wirth, L | 2 |
| Costello, R | 2 |
| Braschayko, P | 1 |
| Allen, A | 1 |
| Mahadevan, A | 1 |
| Flynn, J | 1 |
| Burke, E | 1 |
| Tishler, RB | 1 |
| Tsoutsou, PG | 1 |
| Karpouzis, A | 1 |
| Tsiarkatsi, M | 1 |
| Karapantzos, I | 1 |
| Daniilidis, V | 1 |
| Kouskoukis, C | 1 |
| Liu, CC | 1 |
| Xia, R | 1 |
| Guadagnolo, A | 1 |
| Cormier, JN | 1 |
| Du, XL | 1 |
| Ma, DY | 1 |
| Qiu, WL | 1 |
| Zhang, CP | 1 |
| Saavedra, MM | 1 |
| Henríquez-Hernández, LA | 1 |
| Lara, PC | 1 |
| Pinar, B | 1 |
| Rodríguez-Gallego, C | 1 |
| Lloret, M | 1 |
| Eisbruch, A | 2 |
| Bardet, E | 2 |
| Martin, L | 2 |
| Calais, G | 2 |
| Alfonsi, M | 1 |
| Feham, NE | 1 |
| Tuchais, C | 2 |
| Boisselier, P | 1 |
| Dessard-Diana, B | 1 |
| Seng, SH | 1 |
| Garaud, P | 1 |
| Aupérin, A | 1 |
| Maillard, E | 1 |
| Brizel, DM | 6 |
| Buentzel, J | 2 |
| Langendijk, JA | 2 |
| Komaki, R | 1 |
| Swan Leong, S | 1 |
| Levendag, P | 3 |
| Gosselin, TK | 1 |
| Pavilonis, H | 1 |
| Huang, R | 1 |
| Yu, H | 1 |
| Kuang, A | 1 |
| Giatromanolaki, A | 3 |
| Sivridis, E | 2 |
| Rhein, B | 1 |
| Feham, N | 1 |
| Alphonsi, M | 1 |
| Rosine, D | 1 |
| Braaksma, M | 2 |
| Anné, PR | 3 |
| Nicolatou-Galitis, O | 1 |
| Sotiropoulou-Lontou, A | 1 |
| Velegraki, A | 1 |
| Pissakas, G | 1 |
| Kolitsi, G | 1 |
| Kyprianou, K | 1 |
| Kouloulias, V | 1 |
| Papanikolaou, I | 1 |
| Yiotakis, I | 1 |
| Dardoufas, K | 1 |
| Vacha, P | 2 |
| Fehlauer, F | 2 |
| Mahlmann, B | 2 |
| Marx, M | 2 |
| Hinke, A | 1 |
| Sommer, K | 1 |
| Richter, E | 3 |
| Feyerabend, T | 2 |
| Momm, F | 4 |
| Weissenberger, C | 1 |
| Bartelt, S | 1 |
| Henke, M | 6 |
| Hu, K | 2 |
| Ship, JA | 2 |
| Harrison, LB | 1 |
| Weeks, L | 1 |
| Thorstad, WL | 2 |
| Haughey, B | 2 |
| Chao, KS | 5 |
| Ozyigit, G | 1 |
| Thorsdad, WL | 1 |
| Boehme, S | 1 |
| Wilson, DB | 1 |
| Alberti, W | 1 |
| Machtay, M | 2 |
| Chalian, AA | 1 |
| Lustig, R | 1 |
| Hershock, D | 1 |
| Miller, L | 1 |
| Weinstein, GS | 1 |
| Weber, RS | 2 |
| Cengiz, M | 1 |
| Onal, C | 1 |
| Yildiz, F | 2 |
| Zorlu, AF | 1 |
| Aframian, DJ | 1 |
| Palmon, A | 1 |
| Nahlieli, O | 1 |
| Suntharalingam, M | 1 |
| Jaboin, J | 1 |
| Taylor, R | 1 |
| Wolf, J | 1 |
| Banglore, M | 1 |
| Van Echo, D | 1 |
| Ord, R | 1 |
| Ng, AK | 1 |
| Hickey, G | 1 |
| Li, S | 1 |
| Neuberg, D | 1 |
| Mauch, PM | 1 |
| Chambers, MS | 2 |
| Mazeron, JJ | 2 |
| La Scala, GC | 1 |
| O'Donovan, DA | 1 |
| Yeung, I | 1 |
| Darko, J | 1 |
| Addison, PD | 1 |
| Neligan, PC | 1 |
| Pang, CY | 1 |
| Forrest, CR | 1 |
| Cady, J | 1 |
| Blanco, AI | 1 |
| Amrein, PC | 1 |
| Clark, JR | 1 |
| Supko, JG | 1 |
| Fabian, RL | 1 |
| Wang, CC | 1 |
| Colevas, AD | 1 |
| Posner, MR | 1 |
| Deschler, DG | 1 |
| Rocco, JW | 1 |
| Finkelstein, DM | 1 |
| McIntyre, JF | 1 |
| van Agthoven, M | 1 |
| Nijdam, W | 1 |
| Uyl-de Groot, C | 1 |
| Abitbol, A | 1 |
| Abdel-Wahab, M | 1 |
| Harvey, M | 1 |
| Lewin, A | 1 |
| Troner, M | 1 |
| Hamilton-Nelson, K | 1 |
| Wu, J | 1 |
| Markoe, A | 1 |
| Micke, O | 1 |
| Adamietz, IA | 1 |
| Monnier, A | 3 |
| Glatzel, M | 5 |
| de Vries, A | 1 |
| Wasserman, TH | 4 |
| Eschwege, F | 3 |
| Sauer, R | 5 |
| Strnad, V | 6 |
| Anacak, Y | 1 |
| Kamer, S | 1 |
| Haydaroglu, A | 1 |
| Ozsahin, M | 1 |
| Betz, M | 1 |
| Matzinger, O | 1 |
| Bron, L | 1 |
| Luthi, F | 1 |
| Pasche, P | 1 |
| Azria, D | 1 |
| Mirimanoff, RO | 1 |
| Zouhair, A | 1 |
| Kahn, ST | 1 |
| Johnstone, PA | 1 |
| Garden, AS | 1 |
| Lewin, JS | 1 |
| de Castro, G | 1 |
| Federico, MH | 1 |
| Bensadoun, RJ | 1 |
| Schubert, MM | 1 |
| Lalla, RV | 1 |
| Keefe, D | 1 |
| Jellema, AP | 1 |
| Slotman, BJ | 1 |
| Muller, MJ | 1 |
| Leemans, CR | 1 |
| Smeele, LE | 1 |
| Hoekman, K | 1 |
| Aaronson, NK | 1 |
| Stokman, MA | 1 |
| Spijkervet, FK | 1 |
| Boezen, HM | 1 |
| Schouten, JP | 1 |
| Roodenburg, JL | 1 |
| de Vries, EG | 1 |
| Dest, VM | 1 |
| Morrison, WH | 1 |
| Irwin, DH | 1 |
| Chougule, PB | 1 |
| Estopinal, NC | 1 |
| Berson, A | 1 |
| Curran, WJ | 2 |
| Münter, MW | 1 |
| Hoffner, S | 1 |
| Hof, H | 1 |
| Herfarth, KK | 1 |
| Huber, P | 1 |
| Karger, CP | 1 |
| Veerasarn, V | 1 |
| Phromratanapongse, P | 1 |
| Suntornpong, N | 1 |
| Lorvidhaya, V | 1 |
| Sukthomya, V | 1 |
| Chitapanarux, I | 1 |
| Tesavibul, C | 1 |
| Swangsilpa, T | 1 |
| Khorprasert, C | 1 |
| Shotelersuk, K | 1 |
| Kongthanarat, Y | 1 |
| Panichevaluk, A | 1 |
| Chiewvit, S | 1 |
| Pusuwan, P | 1 |
| Aekmahachai, M | 1 |
| Ratchadara, S | 1 |
| Sirilipoche, S | 1 |
| Saengsuda, Y | 1 |
| Yun, HJ | 1 |
| Bogaerts, J | 1 |
| Awada, A | 1 |
| Lacombe, D | 1 |
| Samuels, MA | 1 |
| Danielidis, V | 1 |
| Law, A | 1 |
| Kennedy, T | 1 |
| Pellitteri, P | 1 |
| Wood, C | 1 |
| Christie, D | 1 |
| Yumen, O | 1 |
| Messerschmidt, GL | 1 |
| Oleka, N | 1 |
| Xunclà, M | 1 |
| Barquinero, JF | 1 |
| Caballín, MR | 1 |
| Craven-Bartle, J | 1 |
| Ribas, M | 1 |
| de Vega, JM | 1 |
| Barrios, L | 1 |
| Valeyrie-Allanore, L | 1 |
| Poulalhon, N | 1 |
| Fagot, JP | 1 |
| Sekula, P | 1 |
| Davidovici, B | 1 |
| Sidoroff, A | 1 |
| Mockenhaupt, M | 1 |
| Takahashi, I | 3 |
| Mitsuhashi, N | 2 |
| Itoh, J | 2 |
| Okazaki, A | 1 |
| Ikeda, H | 1 |
| Suto, H | 2 |
| Yamakawa, M | 1 |
| Nozaki, M | 1 |
| Miyaishi, K | 3 |
| Niibe, H | 3 |
| Kligerman, MM | 1 |
| Forastiere, AA | 1 |
| Urba, SG | 1 |
| McDonald, S | 1 |
| Meyerowitz, C | 1 |
| Smudzin, T | 1 |
| Rubin, P | 1 |
| Büntzel, J | 5 |
| Schuth, J | 2 |
| Küttner, K | 3 |
| Fröhlich, D | 2 |
| Taylor, SE | 1 |
| Miller, EG | 1 |
| Mehta, MP | 1 |
| Planting, AS | 1 |
| Catimel, G | 1 |
| de Mulder, PH | 1 |
| de Graeff, A | 1 |
| Höppener, F | 1 |
| Verweij, J | 1 |
| Oster, W | 3 |
| Vermorken, JB | 1 |
| Bechtold, C | 2 |
| Fischer, K | 2 |
| Tsekos, A | 2 |
| Schultze, J | 1 |
| Kimmig, B | 1 |
| Engel, A | 1 |
| Peters, K | 1 |
| Mücke, R | 1 |
| Hamann, D | 1 |
| Ziegler, PG | 1 |
| Fietkau, R | 1 |
| Schönekäs, KG | 1 |
| Wagner, W | 1 |
| Prott, FJ | 1 |
| Altmann, S | 1 |
| Hoffmanns, H | 1 |
| Weinaug, R | 1 |
| De Crevoisier, R | 1 |
| Abdulkarim, B | 1 |
| Lusinchi, A | 1 |
| Luboinski, B | 1 |
| Wibault, P | 1 |
| Kyrias, G | 1 |
| Kakolyris, S | 1 |
| Kouroussis, C | 1 |
| Frangiadaki, C | 1 |
| Retalis, G | 1 |
| Georgoulias, V | 1 |
| Batcha, M | 1 |
| Zhang, J | 2 |
| Russell, L | 1 |
| Lale Atahan, I | 1 |
| Ozyar, E | 1 |
| Sahin, S | 1 |
| Yalçin, B | 1 |
| Karaduman, A | 1 |
| Wasserman, T | 1 |
| Mackowiak, JI | 1 |
| Peeples, PJ | 1 |
| Meyer, J | 1 |
| Bendel, M | 1 |
| Grötz, K | 1 |
| Schulte, A | 1 |
| Vikram, B | 1 |
| Bennett, CL | 1 |
| Lane, D | 1 |
| Stinson, T | 1 |
| Noël, G | 1 |
| Prescott, LM | 1 |
| Antonadou, D | 1 |
| Pepelassi, M | 1 |
| Synodinou, M | 1 |
| Puglisi, M | 1 |
| Throuvalas, N | 1 |
| Zoberi, I | 1 |
| Maehara, Y | 2 |
| Nakajima, N | 1 |
| Sakaino, K | 1 |
| Matsuura, S | 1 |
| Nagai, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Single Center, Open Label Clinical Investigation on the Treatment of Radiation Induced Dermatitis With Radiation Care® Gel[NCT04995328] | 23 participants (Actual) | Interventional | 2021-08-03 | Completed | |||
| An Open-Label, Proof of Concept, Efficacy, Safety and Tolerability Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for the Prevention and Treatment of Oral Mucositis Induced by Radiation Therapy[NCT02399228] | Phase 2 | 13 participants (Actual) | Interventional | 2015-10-04 | Completed | ||
| Phase II, Randomized Study of Concomitant Chemoradiation Using Weekly Carboplatinum/Paclitaxel With (Arm A) or Without (Arm B) Daily Subcutaneous Amifostine in Patients With Newly Diagnosed Locally Advanced Squamous Cell Cancer of the Head and Neck[NCT00095927] | Phase 2 | 58 participants (Actual) | Interventional | 2003-05-31 | Completed | ||
| A Randomized Phase III Study Comparing Intravenous Versus Subcutaneous Administration of Amifostine in Prevention of Xerostomia for Patients Receiving Radiotherapy for Head and Neck Carcinomas[NCT00158691] | Phase 3 | 296 participants | Interventional | 2001-03-31 | Completed | ||
| Effects of Herbal Products on Reduction of Radiation-induced Dermatitis in Breast Cancer Patients[NCT02922244] | 150 participants (Actual) | Interventional | 2016-05-31 | Completed | |||
| Phase I/II Study of Escalating Doses of Taxol Used Concurrently With Ethyol and Accelerated Hyperfractionated Radiotherapy in the Treatment of Stage III and IV Carcinoma of the Head and Neck[NCT00003193] | Phase 1/Phase 2 | 37 participants (Anticipated) | Interventional | 1998-01-31 | Completed | ||
| Impacts of Oral Supplement With L-Glutamine on the Radiation-induced Toxicity and Nutritional Status of Head and Neck Cancer Patients Under Radiotherapy[NCT03015077] | 59 participants (Actual) | Interventional | 2014-07-31 | Completed | |||
| A Phase III Study of Magic Mouthwash Plus Sucralfate Versus Benzydamine HCl for Treatment of Radiation-induced Oral Mucositis in Head and Neck Cancer Patients.[NCT00814359] | Phase 3 | 67 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| Phase I Trial of Dose Escalated IMRT to the Para-aortic Nodes With Concurrent Cisplatin and Amifostine in Locally Advanced Cervical Cancer[NCT00137358] | Phase 1 | 0 participants (Actual) | Interventional | Withdrawn (stopped due to unable to obtain funding to conduct study) | |||
| "Combined Oncoxin-Viusid® Treatment With Radiotherapy and Chemotherapy in Patients With Head and Neck Cancer. Phase II, Randomized and Double-blind Study"[NCT03541772] | Phase 2 | 60 participants (Actual) | Interventional | 2015-01-20 | Completed | ||
| Normal Tissue Oxygenation Following Radiotherapy[NCT00677040] | 20 participants (Actual) | Observational | 2008-04-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The Radiation Therapy Oncology Group (RTOG) is the measure of anatomical changes associated with oral mucositis. Patients scores will be compared to historical data of patient progression.~RTOG Scoring Criteria- Grade 0(none)- No change over baseline Grade 1(mild)- Irritation, may experience slight pain, not requiring analgesic Grade 2(moderate)- Patchy mucositis that may produce inflammatory serosanguinitis discharge; may experience moderate pain requiring analgesia Grade 3(severe) -Confluent, fibrinous mucositis, may include severe pain requiring narcotic Grade 4(life-threatening)-Ulceration, hemorrhage, or necrosis" (NCT02399228)
Timeframe: Up to ten (10) weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| 0.25% EISO Mouth Rinse | 7 |
"Severity of pain in the oral cavity/oropharynx was measured using the numerical rating pain scale (NRPS) at each study visit. The NRPS is an 11-point scale from 0-10:~0 = No pain 10 = The most intense pain imaginable." (NCT02399228)
Timeframe: Up to ten (10) weeks
| Intervention | score on a scale (Mean) |
|---|---|
| 0.25% EISO Mouth Rinse | 3.875 |
"Adverse Events (AEs) will be assessed in accordance the Common Terminology Criteria for Adverse Events (CTCAE). The number of patients experiencing adverse events possibly, or probably related to the study product will be reported.~Possibly related: A clinical event, including laboratory test abnormality (if applicable), with a reasonable time sequence to administration of the drug, but which could also be explained by concurrent disease or other drugs or chemicals.~Probably related: A clinical event, including laboratory test abnormality (if applicable), with a reasonable time sequence to administration of the drug, unlikely to be attributed to concurrent disease or other drugs or chemicals, and which follows a clinically reasonable response on withdrawal." (NCT02399228)
Timeframe: [ Time Frame: Up to ten (10) weeks ]
| Intervention | participants (Number) | |
|---|---|---|
| Nausea (Mild) | Vomiting (Mild) | |
| 0.25% EISO Mouth Rinse | 2 | 2 |
Transcutaneous oxygen detector is used to measure the partial pressure of oxygen. The unit detects electrolytes ionized by oxygen. The measuring electrode also heats the skin being measured to facilitate maximal bloodflow to the area. (NCT00677040)
Timeframe: One visit for 20 minutes
| Intervention | mmHg (Mean) |
|---|---|
| Subjects | 62.5 |
(NCT00677040)
Timeframe: One visit
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| late subcutaneous toxicitiy score 1 | late subcutaneous toxcity score 2 | late skin toxicity score 1 | late skin toxicity score 2 | |
| Subjects | 19 | 1 | 19 | 1 |
27 reviews available for amifostine anhydrous and Cancer of Head
| Article | Year |
|---|---|
Effect of amifostine in head and neck cancer patients treated with radiotherapy: a systematic review and meta-analysis based on randomized controlled trials.
Topics: Amifostine; Carcinoma, Squamous Cell; Combined Modality Therapy; Head and Neck Neoplasms; Humans; Ra | 2014 |
[Individual patient data meta-analyses of randomized trials for the treatment of non-metastatic head and neck squamous cell carcinomas: Principles, results and perspectives].
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carcinoma, Squamous Cell; Ch | 2015 |
Pharmacologic normal tissue protection in clinical radiation oncology: focus on amifostine.
Topics: Amifostine; Female; Genital Neoplasms, Female; Head and Neck Neoplasms; Humans; Neoplasms; Radiation | 2008 |
Strategies for managing radiation-induced mucositis in head and neck cancer.
Topics: Acetylcysteine; Amifostine; Carcinoma, Squamous Cell; Glutamine; Head and Neck Neoplasms; Humans; In | 2009 |
The role of amifostine in the treatment of head and neck cancer with cisplatin-radiotherapy.
Topics: Amifostine; Antineoplastic Agents; Cisplatin; Combined Modality Therapy; Head and Neck Neoplasms; Hu | 2009 |
[Current status of prevention and management of radiation-induced xerostomia].
Topics: Amifostine; Animals; Head and Neck Neoplasms; Humans; Oral Health; Radiation Injuries; Radiation-Pro | 2010 |
Effect of amifostine on survival among patients treated with radiotherapy: a meta-analysis of individual patient data.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Non-S | 2011 |
Head and neck cancer: managing xerostomia and other treatment induced side effects.
Topics: Amifostine; Fatigue; Head and Neck Neoplasms; Humans; Pain; Pain Management; Skin Abnormalities; Tre | 2002 |
[Radioprotective effects on head and neck tumors of amifostine--a broad-spectrum cytoprotection].
Topics: Amifostine; Animals; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, | 2002 |
Radioprotective effect of amifostine in patients with head and neck squamous cell carcinoma.
Topics: Amifostine; Carcinoma, Squamous Cell; Clinical Trials as Topic; Cytoprotection; Drug Evaluation, Pre | 2002 |
Rationale for integrating high-dose rate intraoperative radiation (HDR-IORT) and postoperative external beam radiation with subcutaneous amifostine for the management of stage III/IV head and neck cancer.
Topics: Amifostine; Clinical Trials as Topic; Head and Neck Neoplasms; Humans; Intraoperative Period; Postop | 2003 |
Toxicity profile of intensity-modulated radiation therapy for head and neck carcinoma and potential role of amifostine.
Topics: Adolescent; Adult; Aged; Amifostine; Combined Modality Therapy; Female; Head and Neck Neoplasms; Hum | 2003 |
Amifostine-induced fever: case report and review of the literature.
Topics: Amifostine; Carcinoma, Squamous Cell; Combined Modality Therapy; Fever; Head and Neck Neoplasms; Hum | 2004 |
Radiotherapy-induced salivary dysfunction.
Topics: Amifostine; Combined Modality Therapy; Head and Neck Neoplasms; Humans; Intraoperative Period; Radia | 2004 |
Navigating external beam radiation therapy for head and neck cancer.
Topics: Amifostine; Carcinoma, Squamous Cell; Combined Modality Therapy; Head and Neck Neoplasms; Humans; Ma | 2005 |
Head and neck squamous cell carcinoma: optimizing the therapeutic index.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modal | 2005 |
Management of xerostomia related to radiotherapy for head and neck cancer.
Topics: Acupuncture Therapy; Amifostine; Clinical Trials as Topic; Head and Neck Neoplasms; Humans; Muscarin | 2005 |
How to reduce radiation-related toxicity in patients with cancer of the head and neck.
Topics: Amifostine; Anti-Infective Agents; Deglutition Disorders; Fibrosis; Free Radical Scavengers; Growth | 2006 |
Evaluation, prevention and management of radiotherapy-induced xerostomia in head and neck cancer patients.
Topics: Amifostine; Carcinoma, Squamous Cell; Clinical Trials as Topic; Cytoplasmic Granules; Free Radical S | 2006 |
Amifostine in the management of radiation-induced and chemo-induced mucositis.
Topics: Amifostine; Antineoplastic Agents; Combined Modality Therapy; Esophagitis; Evidence-Based Medicine; | 2006 |
Preventive intervention possibilities in radiotherapy- and chemotherapy-induced oral mucositis: results of meta-analyses.
Topics: Amifostine; Anti-Bacterial Agents; Antineoplastic Agents; Colony-Stimulating Factors; Cranial Irradi | 2006 |
Preventive intervention possibilities in radiotherapy- and chemotherapy-induced oral mucositis: results of meta-analyses.
Topics: Amifostine; Anti-Bacterial Agents; Antineoplastic Agents; Colony-Stimulating Factors; Cranial Irradi | 2006 |
Preventive intervention possibilities in radiotherapy- and chemotherapy-induced oral mucositis: results of meta-analyses.
Topics: Amifostine; Anti-Bacterial Agents; Antineoplastic Agents; Colony-Stimulating Factors; Cranial Irradi | 2006 |
Preventive intervention possibilities in radiotherapy- and chemotherapy-induced oral mucositis: results of meta-analyses.
Topics: Amifostine; Anti-Bacterial Agents; Antineoplastic Agents; Colony-Stimulating Factors; Cranial Irradi | 2006 |
Radioprotectants: adding quality of life to survivorship?
Topics: Amifostine; Combined Modality Therapy; Head and Neck Neoplasms; Humans; Lung Neoplasms; Neoplasms; O | 2006 |
Clinical trial design limitations in head and neck squamous cell carcinomas.
Topics: Amifostine; Antineoplastic Agents; Carcinoma, Squamous Cell; Combined Modality Therapy; ErbB Recepto | 2007 |
Experimental therapeutic approaches for recurrent head and neck cancer.
Topics: Amifostine; Animals; Antibodies, Monoclonal; Granulocyte-Macrophage Colony-Stimulating Factor; Head | 1995 |
Preemptive pharmacologic intervention in radiation-induced salivary dysfunction.
Topics: Adrenergic beta-Agonists; Amifostine; Animals; Head and Neck Neoplasms; Humans; Iatrogenic Disease; | 1999 |
Amifostine and combined-modality therapeutic approaches.
Topics: Amifostine; Clinical Trials as Topic; Combined Modality Therapy; Cytoprotection; Female; Head and Ne | 1999 |
Radioprotection of head and neck tissue by amifostine.
Topics: Amifostine; Animals; Clinical Trials as Topic; Head and Neck Neoplasms; Humans; Mouth Mucosa; Radiat | 2002 |
46 trials available for amifostine anhydrous and Cancer of Head
| Article | Year |
|---|---|
Randomized double-blind trial of amifostine versus placebo for radiation-induced xerostomia in patients with head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Amifostine; Double-Blind Method; Female; Head and Neck Neoplasms; Hu | 2019 |
Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; C | 2009 |
Radiochemotherapy with cetuximab, cisplatin, and amifostine for locally advanced head and neck cancer: a feasibility study.
Topics: Adult; Aged; Aged, 80 and over; Amifostine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2010 |
Subcutaneous compared with intravenous administration of amifostine in patients with head and neck cancer receiving radiotherapy: final results of the GORTEC2000-02 phase III randomized trial.
Topics: Adult; Aged; Amifostine; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Head and Neck | 2011 |
Preliminary data of the GORTEC 2000-02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy.
Topics: Amifostine; Carcinoma, Squamous Cell; Cytoprotection; Female; Head and Neck Neoplasms; Humans; Injec | 2002 |
Tools for optimal tissue sparing in concomitant chemoradiation of advanced head and neck cancer: subcutaneous amifostine and computed tomography-based target delineation.
Topics: Amifostine; Antineoplastic Agents; Carcinoma, Squamous Cell; Combined Modality Therapy; Cytoprotecti | 2002 |
Phase II trial of subcutaneous amifostine in patients undergoing radiation therapy for head and neck cancer.
Topics: Adult; Aged; Amifostine; Cytoprotection; Dose Fractionation, Radiation; Female; Head and Neck Neopla | 2002 |
Oral candidiasis in head and neck cancer patients receiving radiotherapy with amifostine cytoprotection.
Topics: Amifostine; Candidiasis, Oral; Female; Head and Neck Neoplasms; Humans; Laryngeal Neoplasms; Middle | 2003 |
Randomized phase III trial of postoperative radiochemotherapy +/- amifostine in head and neck cancer. Is there evidence for radioprotection?
Topics: Amifostine; Antineoplastic Agents; Carboplatin; Combined Modality Therapy; Female; Head and Neck Neo | 2003 |
Moist skin care can diminish acute radiation-induced skin toxicity.
Topics: Amifostine; Azulenes; Clinical Trials as Topic; Data Interpretation, Statistical; Dose Fractionation | 2003 |
Phase II randomized study of concomitant chemoradiation using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with newly diagnosed locally advanced squamous cell carcinoma of the head and neck.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; C | 2003 |
Pilot study of subcutaneous amifostine in patients undergoing postoperative intensity modulated radiation therapy for head and neck cancer: preliminary data.
Topics: Amifostine; Carcinoma, Squamous Cell; Head and Neck Neoplasms; Humans; Injections, Subcutaneous; Pil | 2003 |
Toxicity profile of intensity-modulated radiation therapy for head and neck carcinoma and potential role of amifostine.
Topics: Adolescent; Adult; Aged; Amifostine; Combined Modality Therapy; Female; Head and Neck Neoplasms; Hum | 2003 |
Serious adverse effects of amifostine during radiotherapy in head and neck cancer patients.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2004 |
The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT).
Topics: Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous C | 2004 |
Toxicity and compliance of subcutaneous amifostine in patients undergoing postoperative intensity-modulated radiation therapy for head and neck cancer.
Topics: Adult; Amifostine; Carcinoma, Squamous Cell; Combined Modality Therapy; Head and Neck Neoplasms; Hum | 2004 |
A randomized phase II trial of amifostine for head and neck irradiation in lymphoma.
Topics: Adult; Amifostine; Combined Modality Therapy; Head and Neck Neoplasms; Humans; Lymphoma; Quality of | 2004 |
A phase II study to assess the efficacy of amifostine for submandibular/sublingual salivary sparing during the treatment of head and neck cancer with intensity modulated radiation therapy for parotid salivary sparing.
Topics: Amifostine; Carcinoma, Squamous Cell; Head and Neck Neoplasms; Humans; Parotid Gland; Radiation-Prot | 2004 |
Phase I trial and pharmacokinetics of escalating doses of paclitaxel and concurrent hyperfractionated radiotherapy with or without amifostine in patients with advanced head and neck carcinoma.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modal | 2005 |
Costs of treatment intensification for head and neck cancer: concomitant chemoradiation randomised for radioprotection with amifostine.
Topics: Ambulatory Care; Amifostine; Brachytherapy; Combined Modality Therapy; Costs and Cost Analysis; Fema | 2005 |
Phase II study of tolerance and efficacy of hyperfractionated radiation therapy and 5-fluorouracil, cisplatin, and paclitaxel (taxol) and amifostine (ethyol) in head and neck squamous cell carcinomas: A-3 protocol.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Com | 2005 |
Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: a randomized placebo-controlled phase III study.
Topics: Adult; Aged; Amifostine; Antineoplastic Agents; Carboplatin; Combined Modality Therapy; Disease Prog | 2006 |
Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head-and- neck cancer: 2-year follow-up of a prospective, randomized, phase III trial.
Topics: Adult; Amifostine; Carcinoma, Squamous Cell; Chronic Disease; Female; Follow-Up Studies; Head and Ne | 2005 |
Radiotherapy alone, versus radiotherapy with amifostine 3 times weekly, versus radiotherapy with amifostine 5 times weekly: A prospective randomized study in squamous cell head and neck cancer.
Topics: Adult; Aged; Amifostine; Carcinoma, Squamous Cell; Drug Administration Schedule; Female; Head and Ne | 2006 |
A Phase II trial of subcutaneous amifostine and radiation therapy in patients with head-and-neck cancer.
Topics: Adult; Aged; Amifostine; Combined Modality Therapy; Female; Head and Neck Neoplasms; Humans; Inciden | 2007 |
Effect of Amifostine to prevent radiotherapy-induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland function.
Topics: Adult; Aged; Amifostine; Carcinoma, Squamous Cell; Chi-Square Distribution; Female; Head and Neck Ne | 2006 |
Efficacy and safety of subcutaneous amifostine in minimizing radiation-induced toxicities in patients receiving combined-modality treatment for squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squ | 2007 |
Preliminary results of a pilot study using WR-2721 before fractionated irradiation of the head and neck to reduce salivary gland dysfunction.
Topics: Amifostine; Feasibility Studies; Head and Neck Neoplasms; Humans; Parotid Gland; Pilot Projects; Rad | 1994 |
Radiochemotherapy with amifostine cytoprotection for head and neck cancer.
Topics: Adult; Aged; Amifostine; Antineoplastic Agents; Carboplatin; Combined Modality Therapy; Female; Head | 1998 |
Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer.
Topics: Adult; Aged; Amifostine; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Cytoprote | 1998 |
Randomized study of a short course of weekly cisplatin with or without amifostine in advanced head and neck cancer. EORTC Head and Neck Cooperative Group.
Topics: Adult; Aged; Amifostine; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Dose-Response R | 1999 |
[Experiences with sodium selenite in treatment of acute and late adverse effects of radiochemotherapy of head-neck carcinomas. Cytoprotection Working Group in AK Supportive Measures in Oncology Within the scope of MASCC and DKG].
Topics: Adult; Aged; Amifostine; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Combined Modality Therapy | 1999 |
[Alteration of radiation-induced hematotoxicity by amifostine (ethyol)].
Topics: Amifostine; Blood Cells; Blood Platelets; Carcinoma, Squamous Cell; Head and Neck Neoplasms; Hemoglo | 1999 |
[Side effects of postoperative radiochemotherapy with amifostine versus radiochemotherapy alone in head and neck tumors. Preliminary results of a prospective randomized trial].
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Amifostine; Antineoplastic Agents; Carboplatin; Carcinoma, | 1999 |
Supportive use of amifostine in patients with head and neck tumors undergoing radio-chemotherapy. Is it possible to limit the duration of the application of amifostine?
Topics: Adolescent; Adult; Aged; Amifostine; Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; C | 1999 |
[Cytoprotection with amifostine in radiotherapy or radio-chemotherapy of head and neck tumors].
Topics: Adult; Aged; Amifostine; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Comb | 1999 |
A randomized study of very accelerated radiotherapy with and without amifostine in head and neck squamous cell carcinoma.
Topics: Adult; Aged; Amifostine; Carcinoma, Squamous Cell; Drug Administration Schedule; Drug Eruptions; Fea | 2000 |
Subcutaneous administration of amifostine during fractionated radiotherapy: a randomized phase II study.
Topics: Abdominal Neoplasms; Adult; Aged; Amifostine; Chi-Square Distribution; Dose Fractionation, Radiation | 2000 |
Phase III randomized trial of amifostine as a radioprotector in head and neck cancer.
Topics: Adult; Aged; Amifostine; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Male; Mi | 2000 |
Phase III randomized trial of amifostine as a radioprotector in head and neck cancer.
Topics: Adult; Aged; Amifostine; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Male; Mi | 2000 |
Phase III randomized trial of amifostine as a radioprotector in head and neck cancer.
Topics: Adult; Aged; Amifostine; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Male; Mi | 2000 |
Phase III randomized trial of amifostine as a radioprotector in head and neck cancer.
Topics: Adult; Aged; Amifostine; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Male; Mi | 2000 |
Effect of amifostine on patient assessed clinical benefit in irradiated head and neck cancer.
Topics: Activities of Daily Living; Adult; Aged; Amifostine; Combined Modality Therapy; Data Interpretation, | 2000 |
Protective effect of amifostine on dental health after radiotherapy of the head and neck.
Topics: Adult; Aged; Amifostine; Dental Caries; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; | 2000 |
Economic analysis of amifostine as adjunctive support for patients with advanced head and neck cancer: preliminary results from a randomized phase II clinical trial from Germany.
Topics: Amifostine; Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; | 2001 |
Alteration of radiation-induced hematotoxicity by amifostine.
Topics: Amifostine; Blood Platelets; Carcinoma, Squamous Cell; Granulocytes; Head and Neck Neoplasms; Hemogl | 2001 |
Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer.
Topics: Aged; Amifostine; Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Th | 2002 |
A phase II trial of subcutaneous amifostine and radiation therapy in patients with head and neck cancer.
Topics: Acute Disease; Amifostine; Head and Neck Neoplasms; Humans; Injections, Subcutaneous; Nausea; Radiat | 2002 |
[An evaluation of the clinical usefulness of amifostine (YM-08310), radioprotective agent. A double-blind placebo-controlled study. 1. Head and neck tumors].
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Amifostine; Carcinoma, Squamous Cell; Child; Clinical Trial | 1985 |
40 other studies available for amifostine anhydrous and Cancer of Head
| Article | Year |
|---|---|
Novel Formulation Strategy to Improve the Feasibility of Amifostine Administration.
Topics: Administration, Intravenous; Administration, Oral; Amifostine; Animals; Biological Availability; Cel | 2018 |
Preventing Radiation-Induced Injury by Topical Application of an Amifostine Metabolite-Loaded Thermogel.
Topics: Amifostine; Animals; Blood Pressure; Breast Neoplasms; Disease Models, Animal; DNA Damage; Dogs; Dru | 2019 |
The effect of amifostine or IMRT to preserve the parotid function after radiotherapy of the head and neck region measured by quantitative salivary gland scintigraphy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amifostine; Female; Head and Neck Neoplasms; Humans; Mal | 2008 |
Amifostine enhances recovery and expansion of peripheral FAS/CD95+ T- and NK-cell subpopulations during radiotherapy of patients with head-neck cancer.
Topics: Adult; Aged; Amifostine; Apoptosis; CD4-Positive T-Lymphocytes; CD56 Antigen; CD8-Positive T-Lymphoc | 2009 |
Risk of xerostomia in association with the receipt of radiation therapy in older patients with head and neck cancer.
Topics: Aged; Aged, 80 and over; Amifostine; Combined Modality Therapy; Female; Head and Neck Neoplasms; Hum | 2011 |
Amifostine modulates radio-induced apoptosis of peripheral blood lymphocytes in head and neck cancer patients.
Topics: Adult; Aged; Amifostine; Apoptosis; Carcinoma, Squamous Cell; Cells, Cultured; Head and Neck Neoplas | 2010 |
Amifostine in the treatment of head and neck cancer: intravenous administration, subcutaneous administration, or none of the above.
Topics: Amifostine; Combined Modality Therapy; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Infu | 2011 |
Proceedings of the 2nd International Cytoprotection Investigators' Congress. June 6-9, 2002. St Thomas, US Virgin Islands, USA.
Topics: Amifostine; Animals; Breast Neoplasms; Cytoprotection; Female; Head and Neck Neoplasms; Humans; Lung | 2002 |
Down-regulation of intestinal-type alkaline phosphatase in the tumor vasculature and stroma provides a strong basis for explaining amifostine selectivity.
Topics: Alkaline Phosphatase; Amifostine; Antigens, Neoplasm; Biomarkers, Tumor; Breast; Breast Neoplasms; C | 2002 |
Pilot study of postoperative reirradiation, chemotherapy, and amifostine after surgical salvage for recurrent head-and-neck cancer.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2004 |
Comment on: 'Serious adverse effects of amifostine during radiotherapy in head and neck cancer patients' Radiother Oncol 70: 261-264, 2004 by Dr Rades et al.
Topics: Amifostine; Head and Neck Neoplasms; Humans; Lung Neoplasms; Radiation-Protective Agents | 2004 |
[Future therapy strategies for salivary gland impairment].
Topics: Amifostine; Cranial Irradiation; Head and Neck Neoplasms; Humans; Muscarinic Agonists; Pilocarpine; | 2004 |
Amifostine reduces radiation therapy-induced dry mouth in head and neck cancer patients.
Topics: Amifostine; Clinical Trials, Phase III as Topic; Head and Neck Neoplasms; Humans; Radiation-Protecti | 2004 |
[Minutes of the 23th meeting of the European Society for Therapeutic Radiology and Oncology (ESTRO). Amsterdam, 24-28 October 2004].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Amifostine; Antineoplastic Agents, Hormonal; Antineo | 2005 |
Radiation-induced craniofacial bone growth inhibition: efficacy of cytoprotection following a fractionated dose regimen.
Topics: Amifostine; Animals; Cephalometry; Cytoprotection; Dose Fractionation, Radiation; Facial Bones; Grow | 2005 |
Daily subcutaneous amifostine administration during irradiation of pediatric head and neck cancers.
Topics: Adolescent; Amifostine; Child; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans | 2007 |
Established and emerging uses of cytoprotection in head and neck cancer.
Topics: Amifostine; Cytoprotection; Head and Neck Neoplasms; Humans; Radiation Injuries; Radiation-Protectiv | 2006 |
Feasibility and efficacy of subcutaneous amifostine therapy in patients with head and neck cancer treated with curative accelerated concomitant-boost radiation therapy.
Topics: Adult; Aged; Amifostine; Dose Fractionation, Radiation; Dose-Response Relationship, Radiation; Feasi | 2006 |
Chemoradiotherapy for head and neck cancer: 'local' side effects are actually systemic.
Topics: Amifostine; Antineoplastic Agents; Chemotherapy, Adjuvant; Combined Modality Therapy; Deglutition Di | 2006 |
Changes in salivary gland function after radiotherapy of head and neck tumors measured by quantitative pertechnetate scintigraphy: comparison of intensity-modulated radiotherapy and conventional radiation therapy with and without Amifostine.
Topics: Adult; Aged; Amifostine; Dose-Response Relationship, Radiation; Female; Head and Neck Neoplasms; Hum | 2007 |
In regards to Münter et Al. (Int J Radiat Oncol Biol Phys 2007;67:651-659).
Topics: Adult; Aged; Amifostine; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Parotid Gland; | 2007 |
Hypoxia inducible factor (HIf1alpha and HIF2alpha) and carbonic anhydrase 9 (CA9) expression and response of head-neck cancer to hypofractionated and accelerated radiotherapy.
Topics: Amifostine; Antigens, Neoplasm; Antineoplastic Agents; Basic Helix-Loop-Helix Transcription Factors; | 2008 |
In regard to Münter et Al. Changes in salivary gland function after radiotherapy of head and neck tumors measured by quantitative pertechnetate scintigraphy: comparison of intensity-modulated radiotherapy and conventional radiation therapy with and withou
Topics: Amifostine; Dose-Response Relationship, Radiation; Head and Neck Neoplasms; Humans; Parotid Gland; R | 2007 |
Cytogenetic damage induced by radiotherapy. Evaluation of protection by amifostine and analysis of chromosome aberrations persistence.
Topics: Amifostine; Chromosome Aberrations; Female; Head and Neck Neoplasms; Humans; In Situ Hybridization, | 2008 |
Stevens-Johnson syndrome and toxic epidermal necrolysis induced by amifostine during head and neck radiotherapy.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Amifostine; Europe; Female; Head and Neck Neop | 2008 |
[Clinical use of radioprotector amifostine (YM-08310)].
Topics: Adolescent; Adult; Aged; Amifostine; Child; Diarrhea; Female; Head and Neck Neoplasms; Humans; Lymph | 1984 |
Pions, protectors. Examples of a vigorous decade in radiotherapy.
Topics: Amifostine; Animals; Antineoplastic Agents; Drug Evaluation; Drug Therapy, Combination; Elementary P | 1982 |
[New data on cytoprotection in radiotherapy].
Topics: Amifostine; Antineoplastic Agents; Carboplatin; Combined Modality Therapy; Cytoprotection; Double-Bl | 1999 |
[Outcome of primary combined radio-chemotherapy in head and neck tumors with simultaneous salivary gland protection by amifostine].
Topics: Amifostine; Antineoplastic Agents; Carboplatin; Combined Modality Therapy; Head and Neck Neoplasms; | 1999 |
Amifostine--a radioprotector in locally advanced head and neck tumors.
Topics: Adult; Aged; Amifostine; Deglutition Disorders; Female; Head and Neck Neoplasms; Humans; Male; Middl | 1999 |
[Cytoprotection with amifostine in the framework of radiochemotherapy in previously irradiated head and neck carcinoma].
Topics: Adult; Aged; Amifostine; Anemia; Antineoplastic Agents; Brachytherapy; Carboplatin; Combined Modalit | 1999 |
The use of amifostine to prevent xerostomia in patients receiving radiation therapy.
Topics: Amifostine; Head and Neck Neoplasms; Humans; Radiation-Protective Agents; Radiotherapy; Xerostomia | 2000 |
Two cases of Stevens-Johnson syndrome: toxic epidermal necrolysis possibly induced by amifostine during radiotherapy.
Topics: Aged; Amifostine; Drug Eruptions; Female; Head and Neck Neoplasms; Humans; Middle Aged; Radiation-Pr | 2000 |
Phase III randomized trial of amifostine as a radioprotector in head and neck cancer.
Topics: Amifostine; Head and Neck Neoplasms; Humans; Radiation-Protective Agents; Randomized Controlled Tria | 2001 |
[Comments on five clinical trials concerning radiotherapy-induced mucositis in patients with head and neck neoplasms].
Topics: Amifostine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Glutamine; Gran | 2001 |
Highlights of the Eighth European Cancer Conference.
Topics: Amifostine; Antineoplastic Agents; Breast Neoplasms; Camptothecin; Colorectal Neoplasms; Combined Mo | 1995 |
Has the outlook improved for amifostine as a clinical radioprotector.
Topics: Amifostine; Head and Neck Neoplasms; Humans; Radiation-Protective Agents | 2001 |
A prospective, nonrandomized study of the impact of amifostine on subsequent hypothyroidism in irradiated patients with head and neck cancers.
Topics: Amifostine; Animals; Clinical Trials, Phase II as Topic; Head and Neck Neoplasms; Humans; Hypothyroi | 2002 |
Protection of salivary function by intensity-modulated radiation therapy in patients with head and neck cancer.
Topics: Amifostine; Dose-Response Relationship, Radiation; Head and Neck Neoplasms; Humans; Parotid Gland; R | 2002 |
Clinical study of the radioprotective effects of Amifostine (YM-08310, WR-2721) on chronic radiation injury.
Topics: Amifostine; Gallium Radioisotopes; Head and Neck Neoplasms; Humans; Organothiophosphorus Compounds; | 1986 |